Palatin Technologies (NYSE: PTN) is a biopharmaceutical company that develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. For more information, visit the company’s website at
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com